• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by GE HealthCare Technologies Inc.

    6/3/25 4:59:35 PM ET
    $GEHC
    Medical Electronics
    Health Care
    Get the next $GEHC alert in real time by email
    FWP 1 d772939dfwp.htm FWP FWP

    Filed Pursuant to Rule 433

    Relating to Preliminary Prospectus Supplement dated June 3, 2025

    To Prospectus dated June 28, 2024

    Registration File No. 333-280584

    GE HealthCare Technologies Inc.

    June 3, 2025

    $650,000,000 4.800% Senior Notes due 2031

    $850,000,000 5.500% Senior Notes due 2035

    PRICING TERM SHEET

     

    Issuer:   

    GE HealthCare Technologies Inc. (the “Issuer”)

    Trade Date:   

    June 3, 2025

    Settlement Date:   

    June 9, 2025 (T+4)

      

    The Issuer expects to deliver the notes against payment for the notes on or about June 9, 2025, which will be the fourth business day following the date of the pricing of the notes, or “T+4”. Under Rule 15c6-1 under the Exchange Act, trades in the secondary market are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes on any date prior to one business day before settlement will be required, by virtue of the fact that the notes initially will settle T+4, to specify alternative settlement arrangements at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes on any date prior to one business day before settlement should consult their advisors.

    Expected Ratings*:   

    Baa2 / BBB / BBB (Moody’s / S&P / Fitch)

    Offering Format:   

    SEC Registered

    Security Title:   

    4.800% Senior Notes due 2031 (the “2031 Notes”)

    5.500% Senior Notes due 2035 (the “2035 Notes” and, together with the 2031 Notes, the “Notes”)

    Principal Amount:   

    2031 Notes: $650,000,000

    2035 Notes: $850,000,000

    Maturity Date:   

    2031 Notes: January 15, 2031

    2035 Notes: June 15, 2035

    Coupon:   

    2031 Notes: 4.800%

    2035 Notes: 5.500%

    Benchmark Treasury:   

    2031 Notes: UST 4.000% due May 31, 2030

    2035 Notes: UST 4.250% due May 15, 2035

    Benchmark Treasury Price and Yield:   

    2031 Notes: 99-26+; 4.038%

    2035 Notes: 98-08; 4.470%

    Spread to Benchmark Treasury:   

    2031 Notes: +78 basis points (0.78%)

    2035 Notes: +103 basis points (1.03%)


    Yield to Maturity:   

    2031 Notes: 4.818%

    2035 Notes: 5.500%

    Issue Price:   

    2031 Notes: 99.906% of principal amount

    2035 Notes: 99.999% of principal amount

    Proceeds (before expenses and underwriters’ discount):   

    2031 Notes: $649,389,000

    2035 Notes: $849,991,500

    Underwriting Discount   

    2031 Notes: 0.550% of principal amount

    2035 Notes: 0.600% of principal amount

    Interest Payment Dates:   

    2031 Notes: Semiannually on January 15 and July 15

    2035 Notes: Semiannually on June 15 and December 15

    First Interest Payment Date:   

    2031 Notes: January 15, 2026

    2035 Notes: December 15, 2025

    Optional Redemption:   

    Make-Whole Call:

      

    We may redeem the 2031 Notes at any time and from time to time prior to December 15, 2030, at the greater of (i) 100% or (ii) a make-whole price calculated using a discount rate of the Treasury plus 15 basis points, in either case plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

     

    We may redeem the 2035 Notes at any time and from time to time prior to March 15, 2035, at the greater of (i) 100% or (ii) a make-whole price calculated using a discount rate of the Treasury plus 20 basis points, in either case plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

    Par Call:

      

    We may redeem the 2031 Notes on or after December 15, 2030, at par plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

     

    We may redeem the 2035 Notes on or after March 15, 2035, at par plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

    CUSIP:   

    2031 Notes: 36266G AB3

    2035 Notes: 36266G AC1

    ISIN:   

    2031 Notes: US36266GAB32

    2035 Notes: US36266GAC15

    Denominations:   

    $2,000 and integral multiples of $1,000 in excess thereof

    Joint Bookrunners:   

    Citigroup Global Markets Inc.

    J.P. Morgan Securities LLC

    Morgan Stanley & Co. LLC

    Barclays Capital Inc.

    BNP Paribas Securities Corp.

    BofA Securities, Inc.

    Deutsche Bank Securities Inc.

    Goldman Sachs & Co. LLC

    HSBC Securities (USA) Inc.

    Mizuho Securities USA LLC

    SMBC Nikko Securities America, Inc.


    Senior Co-Managers:

      

    ING Financial Markets LLC

    PNC Capital Markets LLC

    Santander US Capital Markets LLC

    SG Americas Securities, LLC

    Standard Chartered Bank**

    Co-Managers:

      

    Academy Securities, Inc.

    Loop Capital Markets LLC

     

    *

    Note: A securities rating is not a recommendation to buy, sell or hold securities and may be revised or withdrawn at any time.

    **

    Standard Chartered Bank will not effect any offers or sales of any notes in the United States unless it is through one or more U.S. registered broker-dealers as permitted by the regulations of FINRA.

    The Issuer has filed a Registration Statement (including a prospectus) with the Securities and Exchange Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Issuer has filed with the Securities and Exchange Commission for more complete information about the Issuer and this Offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Citigroup Global Markets Inc. toll-free at 1-800-831-9146 or J.P. Morgan Securities LLC collect at (212) 834-4533 or Morgan Stanley & Co. LLC at (866) 718-1649.

    Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was automatically generated as a result of this communication being sent by Bloomberg or another email system.

    Get the next $GEHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GEHC

    DatePrice TargetRatingAnalyst
    5/5/2025$73.00Sell → Neutral
    UBS
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    9/26/2024$84.00 → $74.00Neutral → Sell
    UBS
    9/18/2024$100.00Neutral → Buy
    BTIG Research
    9/9/2024$90.00Neutral
    JP Morgan
    8/6/2024$100.00Buy
    Stifel
    5/30/2024$87.00Neutral
    Goldman
    More analyst ratings

    $GEHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

      BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

      6/2/25 8:00:00 AM ET
      $GEHC
      $LNTH
      Medical Electronics
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommend Use of FES PET Imaging for Lobular Breast Cancer

      NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer (ILC), which could facilitate greater diagnostic accuracy, earlier interventions, better clinical decision-making and broader insurance coverage for breast cancer patients. GE HealthCare's Cerianna (fluoroestradiol F18) injection is the first and only U.S. Food and Drug Administration (FDA) approved imaging agent to help clinicians assess estrogen receptor positive (ER+) lesion status in recurrent or metastatic breast cancer. GE HealthCare (NASDAQ:GEHC) today announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for clinicians now recommend considerin

      5/30/25 9:20:00 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare launches CleaRecon DL, introducing AI-based 3D reconstruction to the interventional suite

      CleaRecon DL receives 510(k) clearance and CE mark, paving the way for clinicians to use 3D image guidance technologies to their full potential with the goal of achieving better clinical and operational outcomes AI-driven solution advances image quality and improves clinical confidence, encouraging adoption of cone-beam computed tomography GE HealthCare (NASDAQ:GEHC) today announced the launch of CleaRecon DL, technology powered by a deep-learning algorithm, to improve the quality of cone-beam computed tomography (CBCT) images. This artificial intelligence (AI)-driven solution is designed to remove streak artifacts caused by the pulsatile nature of blood flow in the arteries and change

      5/15/25 8:00:00 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Saccaro James covered exercise/tax liability with 9,712 shares, decreasing direct ownership by 14% to 61,832 units (SEC Form 4)

      4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

      6/3/25 4:08:47 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • Director Lavizzo-Mourey Risa J was granted 3,092 shares, increasing direct ownership by 44% to 10,157 units (SEC Form 4)

      4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

      5/30/25 6:05:52 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • Director Lesjak Catherine A was granted 3,092 shares, increasing direct ownership by 51% to 9,116 units (SEC Form 4)

      4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

      5/30/25 6:00:12 PM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    SEC Filings

    See more
    • GE HealthCare Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

      6/4/25 4:50:31 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • SEC Form FWP filed by GE HealthCare Technologies Inc.

      FWP - GE HealthCare Technologies Inc. (0001932393) (Subject)

      6/3/25 4:59:35 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

      5/30/25 8:59:24 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    Financials

    Live finance-specific insights

    See more
    • GE HealthCare reports first quarter 2025 financial results

      Revenue growth was 3% year-over-year; Organic revenue growth* was 4% Net income margin was 11.8% versus 8.0% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.0% versus 14.7% Diluted earnings per share (EPS) were $1.23 versus $0.81 for the prior year; Adjusted EPS* was $1.01 versus $0.90 Cash flow from operating activities was $250 million versus $419 million for the prior year; Free cash flow* was $98 million versus $274 million Updates full-year 2025 guidance Board of Directors authorizes a $1 billion share repurchase program GE HealthCare (NASDAQ:GEHC) today reported financial results for the first quarter ended March 31, 2025. GE He

      4/30/25 6:20:00 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare to announce first quarter 2025 results on April 30, 2025

      GE HealthCare (NASDAQ:GEHC) will announce its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical techno

      4/17/25 4:01:00 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare announces cash dividend for first quarter of 2025

      The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2025 payable on May 15, 2025 to all shareholders of record as of April 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than

      3/27/25 11:34:00 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    Leadership Updates

    Live Leadership Updates

    See more
    • PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

      BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

      6/2/25 8:00:00 AM ET
      $GEHC
      $LNTH
      Medical Electronics
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

      GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

      4/9/25 9:00:00 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare's MIM Software collaborates with Elekta to help enhance radiation therapy treatments and improve patient outcomes

      Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy

      4/22/24 7:07:00 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • GE HealthCare upgraded by UBS with a new price target

      UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00

      5/5/25 8:34:55 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare upgraded by Goldman with a new price target

      Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously

      3/11/25 7:35:30 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare upgraded by Jefferies with a new price target

      Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously

      1/8/25 7:50:38 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jimenez Frank R bought $100,624 worth of shares (1,315 units at $76.52), increasing direct ownership by 2% to 75,796 units (SEC Form 4)

      4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

      5/2/24 6:00:38 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

      SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

      11/12/24 12:53:28 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

      SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

      10/22/24 4:16:16 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • SEC Form SC 13G/A filed by GE HealthCare Technologies Inc. (Amendment)

      SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

      4/2/24 4:07:29 PM ET
      $GEHC
      Medical Electronics
      Health Care